These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 35569559)

  • 21. New techniques for drug delivery to the posterior eye segment.
    Eljarrat-Binstock E; Pe'er J; Domb AJ
    Pharm Res; 2010 Apr; 27(4):530-43. PubMed ID: 20155388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacy.
    Nentwich MM; Ulbig MW
    Dtsch Arztebl Int; 2012 Sep; 109(37):584-90. PubMed ID: 23093988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nanoparticles for the treatment of ocular neovascularizations.
    Hennig R; Goepferich A
    Eur J Pharm Biopharm; 2015 Sep; 95(Pt B):294-306. PubMed ID: 25758124
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 2nd Ophthalmic Drug Development and Delivery Summit.
    Marra M; Gukasyan HJ; Raghava S; Kompella UB
    Expert Opin Drug Deliv; 2007 Jan; 4(1):77-85. PubMed ID: 17184164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent perspectives on the delivery of biologics to back of the eye.
    Joseph M; Trinh HM; Cholkar K; Pal D; Mitra AK
    Expert Opin Drug Deliv; 2017 May; 14(5):631-645. PubMed ID: 27573097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes.
    Amrite A; Pugazhenthi V; Cheruvu N; Kompella U
    Expert Opin Drug Deliv; 2010 May; 7(5):631-45. PubMed ID: 20205602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the Ocular Delivery of Ranibizumab.
    Elsaid N; Jackson TL; Elsaid Z; Alqathama A; Somavarapu S
    Mol Pharm; 2016 Sep; 13(9):2923-40. PubMed ID: 27286558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
    Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
    Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema.
    Fong AH; Lai TY
    Clin Interv Aging; 2013; 8():467-83. PubMed ID: 23766636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cubosomes and other potential ocular drug delivery vehicles for macromolecular therapeutics.
    Hartnett TE; O'Connor AJ; Ladewig K
    Expert Opin Drug Deliv; 2015; 12(9):1513-26. PubMed ID: 25745885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel Eye Drop Formulation for Potential Treatment of Neovascular Age-Related Macular Degeneration.
    Huang WC; Cheng F; Chen CC; Kuo PH; Wang YJ; Yin SC; Tu CM; Wu MH; Wang WY; Chen SE
    Transl Vis Sci Technol; 2021 Dec; 10(14):23. PubMed ID: 34932116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Delivery of therapeutics for deep-seated ocular conditions - status quo.
    Nguyen H; Eng S; Ngo T; Dass CR
    J Pharm Pharmacol; 2018 Aug; 70(8):994-1001. PubMed ID: 29675844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases.
    Seah I; Zhao X; Lin Q; Liu Z; Su SZZ; Yuen YS; Hunziker W; Lingam G; Loh XJ; Su X
    Eye (Lond); 2020 Aug; 34(8):1341-1356. PubMed ID: 32001821
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intractable Ocular Diseases and Treatment Progress.
    Zhang X; Li S; Tang Y; Guo Y; Gao S
    AAPS PharmSciTech; 2020 Aug; 21(6):236. PubMed ID: 32803351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and emerging therapies for ocular neovascularisation.
    Reynolds AL; Kent D; Kennedy BN
    Adv Exp Med Biol; 2014; 801():797-804. PubMed ID: 24664773
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
    Eyetech Study Group
    Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and Characterisation of Photocrosslinked poly(ethylene glycol) diacrylate Implants for Sustained Ocular Drug Delivery.
    McAvoy K; Jones D; Thakur RRS
    Pharm Res; 2018 Jan; 35(2):36. PubMed ID: 29368249
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
    Jonas JB
    Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.